{"id":"W2945244577","doi":"10.1016/j.clcc.2019.05.003","title":"Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)","year":2019,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; McGill University; University of Toronto; Jewish General Hospital","funders":"Cilag; Genentech; Servier; Five Prime Therapeutics; Sirtex Medical; Terumo; Takeda Pharmaceutical Company; Merck KGaA; Gilead Sciences; Roche; Novartis; Meso Scale Diagnostics; Sanofi; Merck; British Microcirculation Society; Amgen; Pfizer; Celgene; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Aflibercept; FOLFIRI; Medicine; Colorectal cancer; Oncology; Quality of life (healthcare); Internal medicine; Cancer; Bevacizumab; Irinotecan; Chemotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006890943,0.0004827234,0.002506914,0.00004231822,0.0002335466,0.00002179614,0.0001905801,0.0002207101,0.0008079042],"category_scores_gemma":[0.0003307561,0.0003165442,0.0007140092,0.0005235606,0.000663713,0.0001006085,0.000114994,0.0002355322,0.0000060115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001181041,"about_ca_system_score_gemma":0.001841129,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01082399,"about_ca_topic_score_gemma":0.03606272,"domain_scores_codex":[0.9955558,0.0003225878,0.002333171,0.0008095769,0.0004327706,0.0005461324],"domain_scores_gemma":[0.995548,0.002182168,0.001090688,0.0003750525,0.0004350129,0.0003690891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02366981,0.002241218,0.848884,0.0004249444,0.004670264,0.00000355588,0.00247218,0.00009617113,0.0001573696,0.0004419342,0.001319153,0.1156194],"study_design_scores_gemma":[0.01659168,0.01509363,0.9529589,0.0002275734,0.0009454667,0.000003384751,0.0007571153,0.000807122,0.0001403099,0.0003625831,0.01180308,0.00030918],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9608063,0.02043627,0.00001650554,0.006748364,0.001053848,0.006057118,0.004373946,0.00009130386,0.0004163537],"genre_scores_gemma":[0.9897147,0.005375082,0.001124235,0.0008527844,0.0002439551,0.001725163,0.0003866476,0.00004966956,0.0005277412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1153102,"threshold_uncertainty_score":0.9999287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1939368141335871,"score_gpt":0.4612977363386604,"score_spread":0.2673609222050733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}